Search

Your search keyword '"Luppa, Peter B."' showing total 645 results
Start Over Author "Luppa, Peter B."
645 results on '"Luppa, Peter B."'

3. German Society for Clinical Chemistry and Laboratory Medicine – areas of expertise: Division reports from the German Congress of Laboratory Medicine 2022 in Mannheim, 13–14 October 2022

Author

Nauck Matthias, Holdenrieder Stefan, Klein Hanns-Georg, Findeisen Peter, Winter Christof, Ceglarek Uta, Petersmann Astrid, Klouche Mariam, Lichtinghagen Ralf, Biemann Ronald, Adler Jakob, Streichert Thomas, von Meyer Alexander, Wieland Eberhard, Hofmann Walter, Aufenanger Johannes, Orth Matthias, Shipkova Maria, Bidlingmaier Martin, Birschmann Ingvild, Blüthner Martin, Conrad Karsten, Luppa Peter B., Kiehntopf Michael, Bietenbeck Andreas, Baum Hannsjörg, and Renz Harald

Subjects
german congress for laboratory medicine 2022, german society for clinical chemistry and laboratory medicine (dgkl), areas of expertise, division reports, Medical technology, R855-855.5
Abstract

The programme of the German Congress for Laboratory Medicine 2022 was essentially designed by the divisions of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). Almost all chairpersons of the divisions organised a 90-min symposium on current topics, i.e. conceptualised the symposia and invited speakers. For this article all chairpersons summarised the lectures that were given within the symposia. The DGKL’s work is structured into 5 areas of expertise: Molecular Diagnostics, Learning & Teaching, Quality & Management, Laboratory & Diagnostics and Biobanks & Informatics. The areas of expertise are in turn subdivided into divisions. About the history of the establishment of this new structure within the DGKL you can find information in the editorial of this issue.

Published
2024
Full Text
View/download PDF

5. Classification of “Near-patient” and “Point-of-Care” SARS-CoV-2 Nucleic Acid Amplification Test Systems and a first approach to evaluate their analytical independence of operator activities

Author

Buchta, Christoph, Zeichhardt, Heinz, Badrick, Tony, Coucke, Wim, Wojtalewicz, Nathalie, Griesmacher, Andrea, Aberle, Stephan W., Schellenberg, Ingo, Jacobs, Ellis, Nordin, Gunnar, Schweiger, Christian, Schwenoha, Karin, Luppa, Peter B., Gassner, Ulrich M., Wagner, Thomas, and Kammel, Martin

Published
2023
Full Text
View/download PDF

7. An integrated device for fast and sensitive immunosuppressant detection

Author

Tombelli, Sara, Trono, Cosimo, Berneschi, Simone, Berrettoni, Chiara, Giannetti, Ambra, Bernini, Romeo, Persichetti, Gianluca, Testa, Genni, Orellana, Guillermo, Salis, Francesca, Weber, Susanne, Luppa, Peter B., Porro, Giampiero, Quarto, Giovanna, Schubert, Markus, Berner, Marcel, Freitas, Paulo P., Cardoso, Susana, Franco, Fernando, Silverio, Vânia, Lopez-Martinez, Maria, Hilbig, Urs, Freudenberger, Kathrin, Gauglitz, Günter, Becker, Holger, Gärtner, Claudia, O’Connell, Mark T., and Baldini, Francesco

Published
2022
Full Text
View/download PDF

9. Rational clinical use of near-patient analytical systems for molecular detection of infectious agents

Author

Luppa Peter B., Rabenau Holger F., Gässler Norbert, Huzly Daniela, Nauck Matthias, Reischl Udo, Schoerner Christoph, and Zeichhardt Heinz

Subjects
infectious agents, nucleic acid testing, poct, Medical technology, R855-855.5
Abstract

Tests for diagnosing infectious diseases (ID-POCT) play a special role among the available point-of-care testing (POCT) methods.

Published
2021
Full Text
View/download PDF

10. Future POCT systems

Author

Vashist, Sandeep K., Luong, John H. T., Luppa, Peter B., Junker, Ralf, Luppa, Peter B., editor, and Junker, Ralf, editor

Published
2018
Full Text
View/download PDF

12. Implementation of POCT

Author

Gässler, Norbert, Luppa, Peter B., Bietenbeck, Andreas, Petersmann, Astrid, Pröbstl, Alexander, Romann, Daniel, Junker, Ralf, Luppa, Peter B., editor, and Junker, Ralf, editor

Published
2018
Full Text
View/download PDF

17. Immunological methods

Author

Luppa, Peter B., Junker, Ralf, Schimke, Ingolf, Stürenburg, Enno, Luppa, Peter B., editor, and Junker, Ralf, editor

Published
2018
Full Text
View/download PDF

23. Why hemolysis detection should be an integral part of any near-patient blood gas analysis

Author

Möckel Martin and Luppa Peter B.

Subjects
blood gas analysis, hemolysis, patient safety, point-of-care (poc), pre-analytical errors, Medical technology, R855-855.5
Abstract

Blood gas analysis at or near the patient’s bedside is a common practice in acute medicine and plays a crucial role in the diagnosis and management of patient’s respiratory status, metabolites, electrolytes, co-oximetry and acid–base balance. Pre-analytical quality aspects of the specimens are getting more and more attention, including the presence of potential interferences. Central laboratories have implemented technologies to detect interferences such as hemolysis, lipidemia or hyperbilirubinemia in blood samples to ensure the highest possible quality in results provided to routine care. However, systematic detection for interference due to hemolysis is currently not in place for blood gas analysis at the point-of-care (POC). To apply hemolysis detection solutions at the central laboratory, but not at the POC for blood gas analysis, is a clear contradiction when novel hemolysis detecting technologies are available. The introduction of a system that systematically detects hemolysis in connection to POC blood gas analysis would be imperative to patient safety and costs associated with potential clinical malpractice (leading to wrong, missing and/or delayed treatment) and would also ensure better compliance to CLSI guidelines and ISO standards, and be beneficial for patient and staff.

Published
2021
Full Text
View/download PDF

27. SERS-based detection of the antibiotic ceftriaxone in spiked fresh plasma and microdialysate matrix by using silver-functionalized silicon nanowire substrates

Author

Liu, Chen, primary, Franceschini, Célia, additional, Weber, Susanne, additional, Dib, Tony, additional, Liu, Poting, additional, Wu, Long, additional, Farnesi, Edoardo, additional, Zhang, Wen-shu, additional, Sivakov, Vladimir, additional, Luppa, Peter B., additional, Popp, Jürgen, additional, and Cialla-May, Dana, additional

Published
2024
Full Text
View/download PDF

29. The extended internal QC (eIQC): a new practical approach for quality assurance in point-of-care glucose testing using the POCTopus Software – a pilot study

Author

von Meyer Alexander, Luppa Peter B., and Cadamuro Janne

Subjects
internal quality control, poct, point-of-care testing, quality assurance, quality control scheme, software, Medical technology, R855-855.5
Abstract

Quality assurance (QA) in point-of-care testing (POCT) is an important issue for organizing POCT structures within the healthcare sector. In Germany, only one device needs to participate in an external QA program, if the responsible core laboratory is supervising internal quality controls of all other identical POCT devices. This flexible definition of quality control (QC) testing is in line with the fundamentals of ISO 22870 and the ISO 15189, but can only be regarded as a minimum requirement.

Published
2020
Full Text
View/download PDF

32. Implementierung von POCT

Author

Gässler, Norbert, Luppa, Peter B., Bietenbeck, Andreas, Petersmann, Astrid, Pröbstl, Alexander, Romann, Daniel, Junker, Ralf, Luppa, Peter B., editor, and Junker, Ralf, editor

Published
2017
Full Text
View/download PDF

43. Neue diagnostische Ansätze zur Früherkennung des akuten Nierenversagens

Author

Luppa, Peter B. (Prof. Dr.), Luppa, Peter B. (Prof. Dr.);Lahmer, Tobias (Priv.-Doz. Dr.), Temori, Farid, Luppa, Peter B. (Prof. Dr.), Luppa, Peter B. (Prof. Dr.);Lahmer, Tobias (Priv.-Doz. Dr.), and Temori, Farid

Abstract

Das akute Nierenversagen stellt eine schwerwiegende Erkrankung dar. Die Diagnostik in den Klassifikationssystemen AKIN und RIFLE beruht auf Urinausscheidung und Serumkreatinin, beides unzureichend. Die Studie hatte zum Ziel, mögliche Vorteile der Biomarker Harnstoff, Cystatin C, TIMP-2 und IGFBP-7 gegenüber Serumkreatinin aufzuzeigen. Es wurden 53 ICU-Patienten zu fünf Messzeitpunkten auf die o.g. Kenngrößen untersucht. Die Biomarker Cystatin C, TIMP-2 und IGFBP-7 wiesen zu allen Messzeiten miteinander hohe Korrelationen auf und reagierten besonders sensibel auf Veränderungen der Nierenleistung., Acute kidney failure is a serious illness. The diagnosis in the classification systems AKIN and RIFLE is based on urine excretion and serum creatinine, both of which are inadequate. The aim of the study was to show possible advantages of the biomarkers urea, cystatin C, TIMP-2 and IGFBP-7 compared to serum creatinine. 53 ICU patients were examined for the above parameters at five measurement times. The biomarkers cystatin C, TIMP-2 and IGFBP-7 showed high correlations with each other at all measurement times and reacted particularly sensitively to changes in kidney performance.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results